TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28640136

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise (NSE)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise with a behavioral approach (NSEB)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Prescription of physical activity (PPA)
Number of subjects: 216
Study: 25542740

Group type: EXPERIMENTAL
Intervention: Standardised (plain) cigarette packaging
Number of subjects: 30

Group type: COMPARATOR
Intervention: Manufacturer-designed (branded) cigarette packaging
Number of subjects: 30
Study: 23992003

Group type: EXPERIMENTAL
Intervention: Fine Needle Aspiration (FNA)
Number of subjects: 100
Study: 21825283

Group type: EXPERIMENTAL
Intervention: supervised moderate‐intensity physical activity program
Number of subjects: 1600

Group type: COMPARATOR
Intervention: successful aging health education program
Number of subjects: 1600
Study: 19664253

Group type: EXPERIMENTAL
Intervention: Terlipressin (1.3 microg.kg‐1.h‐1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Vasopressin (.03 U.min‐1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Norepinephrine (15 microg.min‐1)
Number of subjects: 45
Study: 17209185

Group type: COMPARATOR
Intervention: Physical activity level (PAL) of 1.4
Number of subjects: 10

Group type: COMPARATOR
Intervention: Physical activity level (PAL) of 1.6
Number of subjects: 10

Group type: COMPARATOR
Intervention: Physical activity level (PAL) of 1.8
Number of subjects: 10
Study: 15140756

Group type: EXPERIMENTAL
Intervention: Growth hormone replacement (GHR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PTH‐(1‐34) infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GHR
Number of subjects: 0
Study: 11236299

Group type: EXPERIMENTAL
Intervention: Becotide (innovator formulation)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Beclate (generic formulation)
Number of subjects: 36
Study: 9504622

Group type: EXPERIMENTAL
Intervention: Suction instrument used in 24 ears
Number of subjects: 27

Group type: COMPARATOR
Intervention: No suction instrument used in 27 ears
Number of subjects: 27
Study: 9094727

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 20
Study: 2031258

Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg daily for 14 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6294175

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 59

Group type: COMPARATOR
Intervention: Cimetidine 1 g daily
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily (open treatment)
Number of subjects: 59
Study: 30523522

Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate (PP1M) (50-150 mg equivalent)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Oral Paliperidone Extended Release (ER) (6-12 mg/day)
Number of subjects: 72
Study: 28197844

Group type: EXPERIMENTAL
Intervention: nVNS + SoC
Number of subjects: 97
Study: 25277322

Group type: EXPERIMENTAL
Intervention: Solid lipid curcumin (400 mg as Longvida)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24868098

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Platinum-based doublet chemotherapy
Number of subjects: 174
Study: 22488006

Group type: EXPERIMENTAL
Intervention: Heparin (3 mL, 10 units/mL)
Number of subjects: 341

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (NaCl, 10 mL)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 341

Group type: COMPARATOR
Intervention: 0.9% sodium chloride
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Pressure‐injectable central venous catheters
Number of subjects: 341
Study: 19282274

Group type: EXPERIMENTAL
Intervention: Fixed combination of perindopril and indapamide
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11140
Study: 17900994

Group type: EXPERIMENTAL
Intervention: Asimadoline, up to 1 mg 4 times daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Asimadoline
Number of subjects: 100
Study: 15287950

Group type: EXPERIMENTAL
Intervention: Education about warfarin
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Education and self-monitoring
Number of subjects: 125

Group type: COMPARATOR
Intervention: Usual clinic care
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Education alone
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Education or education and self-monitoring
Number of subjects: 125
Study: 12373472

Group type: EXPERIMENTAL
Intervention: Enoximone (initial bolus 0.5 mg/kg followed by continuous infusion of 2.5 micro g/kg per minute until the 2nd postoperative day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 40
Study: 9191584

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (lactose in decaffeinated coffee)
Number of subjects: 0
Study: 1539785

Group type: EXPERIMENTAL
Intervention: 2% propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% propofol
Number of subjects: 0
Study: 3886153

Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg four times daily for 8 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 31202902

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 28
Study: 29528941

Group type: EXPERIMENTAL
Intervention: UNITY peer support workshop
Number of subjects: 239

Group type: COMPARATOR
Intervention: breast cancer education control group
Number of subjects: 239
Study: 27216354

Group type: EXPERIMENTAL
Intervention: Cold pack
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control
Number of subjects: 99

Group type: COMPARATOR
Intervention: No cold pack
Number of subjects: 99
Study: 25326163

Group type: EXPERIMENTAL
Intervention: Lithium plus usual care
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 56
Study: 22270468

Group type: EXPERIMENTAL
Intervention: Local infiltration of 160 mL of levobupivacaine with adrenaline
Number of subjects: 96

Group type: COMPARATOR
Intervention: No local infiltration
Number of subjects: 96
Study: 20545574

Group type: EXPERIMENTAL
Intervention: Post-operative radiotherapy (RT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No post-operative radiotherapy (Control)
Number of subjects: 0
Study: 17631078

Group type: EXPERIMENTAL
Intervention: Left pectoral implant
Number of subjects: 627

Group type: COMPARATOR
Intervention: Right pectoral implant
Number of subjects: 627
Study: 15704481

Group type: EXPERIMENTAL
Intervention: Phezam treatment for 8 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Phezam treatment for 2 months in routine practice
Number of subjects: 120
Study: 11833047

Group type: EXPERIMENTAL
Intervention: Phytosterol ester-enriched margarine (20 g/d, 1.82 g/d of phytosterols)
Number of subjects: 63
Study: 10610081

Group type: EXPERIMENTAL
Intervention: Exercise (aerobic and resistance)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise addiction
Number of subjects: 0
Study: 7793225

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pipecuronium
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Doxacurium
Number of subjects: 24

Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 24
Study: 1678543

Group type: EXPERIMENTAL
Intervention: sodium divalproex
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 6133412

Group type: EXPERIMENTAL
Intervention: 15 mg midazolam
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 1 mg flunitrazepam
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 30936001

Group type: EXPERIMENTAL
Intervention: 3-step intervention (automated text messages/phone calls, manual phone calls, face-to-face interviews)
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Standard invitation letter (control group)
Number of subjects: 1220
Study: 29305254

Group type: EXPERIMENTAL
Intervention: Total abdominal hysterectomy
Number of subjects: 381

Group type: COMPARATOR
Intervention: Total laparoscopic hysterectomy
Number of subjects: 381
Study: 27966409

Group type: EXPERIMENTAL
Intervention: Men's Safer Sex website plus usual care (n=84)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Usual clinic care only (n=75)
Number of subjects: 159
Study: 24503762

Group type: EXPERIMENTAL
Intervention: Baseline uric acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time‐varying uric acid increase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary outcome
Number of subjects: 0
Study: 22699924

Group type: EXPERIMENTAL
Intervention: High-dose IV furosemide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose IV furosemide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous infusion of IV furosemide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bolus infusion of IV furosemide
Number of subjects: 0
Study: 20678688

Group type: EXPERIMENTAL
Intervention: Test formulation of esomeprazole 40 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of esomeprazole 40 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Comparison of test and reference formulations
Number of subjects: 24
Study: 17416124

Group type: EXPERIMENTAL
Intervention: C1-C2 self-sustained natural apophyseal glide (SNAG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 16239128

Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y gastric bypass surgery
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Dietary interventions of differing macronutrient composition
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Diverse pharmacologic interventions
Number of subjects: 350

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 350
Study: 12201829

Group type: EXPERIMENTAL
Intervention: GH replacement therapy (continuous for 9 years)
Number of subjects: 85

Group type: COMPARATOR
Intervention: No GH replacement therapy
Number of subjects: 85
Study: 9843170

Group type: EXPERIMENTAL
Intervention: rFVIIa 90 microg/kg
Number of subjects: 29

Group type: COMPARATOR
Intervention: rFVIIa 35 microg/kg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: rFVIIa 90 microg/kg (open-label after day 5)
Number of subjects: 29
Study: 7521636

Group type: EXPERIMENTAL
Intervention: APDT vaccines (liquid and freeze-dried)
Number of subjects: 89

Group type: COMPARATOR
Intervention: WCPDT vaccine
Number of subjects: 89
Study: 2658335

Group type: EXPERIMENTAL
Intervention: 250 ml NaCl with 25 ml Ginkgo‐biloba‐extract
Number of subjects: 24

Group type: COMPARATOR
Intervention: 250 ml NaCl without Ginkgo‐biloba‐extract
Number of subjects: 24
Study: 31500590

Group type: EXPERIMENTAL
Intervention: Interprofessional shared decision making (IP-SDM) training for home care teams
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Caregiver characteristics
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Relationship characteristics
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Caregiver's perception of social support resources
Number of subjects: 296
Study: 27145299

Group type: EXPERIMENTAL
Intervention: Iodized salt intervention
Number of subjects: 1602

Group type: COMPARATOR
Intervention: Control group (non-iodized salt)
Number of subjects: 1602

Group type: EXPERIMENTAL
Intervention: Iodized salt intervention (with mother's education as effect modifier)
Number of subjects: 1602

Group type: COMPARATOR
Intervention: Control group (with mother's education as effect modifier)
Number of subjects: 1602
Study: 25559589

Group type: EXPERIMENTAL
Intervention: 10,600 nm CO2 fractional laser (energy = 10 mJ; density = 10%; spot size = 7 mm; pulse = 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (untreated scar half)
Number of subjects: 20
Study: 23264827

Group type: EXPERIMENTAL
Intervention: Clinical care pathway implementation
Number of subjects: 114
Study: 19714349

Group type: EXPERIMENTAL
Intervention: Oral steroid (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 24
Study: 18474024

Group type: EXPERIMENTAL
Intervention: Cyclosporin (CsA) and/or methotrexate (MTX) for GVHD prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emerging strategies for GVHD prophylaxis
Number of subjects: 0
Study: 15793525

Group type: EXPERIMENTAL
Intervention: Tri-herbal combination of Eleutherococcus, Achillea millefolium, and Lamium album
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 12483453

Group type: EXPERIMENTAL
Intervention: Nisoldipine (20 mg day(-1))
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 10051081

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 43
Study: 7564084

Group type: EXPERIMENTAL
Intervention: Cool dialysate (35.0 degrees C)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Warm dialysate (37.5 degrees C)
Number of subjects: 9
Study: 2267679

Group type: EXPERIMENTAL
Intervention: 10(9) irradiation‐killed M. vaccae
Number of subjects: 38

Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tuberculin plus murabutide plus 10(9) irradiated M. vaccae
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Autoclaved preparation of 10(9) M. vaccae
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 2 x 10(9) irradiated M. vaccae
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Most effective modifications
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Autoclaved bacilli
Number of subjects: 38
Study: 7398003

Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 31926496

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 72
Study: 29776383

Group type: EXPERIMENTAL
Intervention: Face-to-face psychoeducation
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Telephone assisted self-help (TASH)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Waiting control group (3-month waiting period)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Counseling (for full responders)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Counseling only or Counseling and neurofeedback (for partial responders)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment only or Pharmacological treatment and neurofeedback (for non-responders)
Number of subjects: 279
Study: 27504751

Group type: EXPERIMENTAL
Intervention: Common Sense Parenting (CSP)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: CSP-Plus
Number of subjects: 321

Group type: COMPARATOR
Intervention: Minimal-contact control condition
Number of subjects: 321
Study: 24615831

Group type: EXPERIMENTAL
Intervention: Intimacy Enhancement (IE) intervention
Number of subjects: 23

Group type: COMPARATOR
Intervention: Wait list control condition
Number of subjects: 23
Study: 23220809

Group type: EXPERIMENTAL
Intervention: Electrotherapy and exercise (hotpack application, ultrasound, and exercise training)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (two weeks rest)
Number of subjects: 60
Study: 19714757

Group type: EXPERIMENTAL
Intervention: Visilizumab 5 microg/kg/day for 2 days
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Visilizumab 7.5 microg/kg/day for 2 days
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Visilizumab 10 microg/kg/day for 2 days
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Visilizumab 12.5 microg/kg/day for 2 days
Number of subjects: 104
Study: 18694678

Group type: EXPERIMENTAL
Intervention: Two-compound scalp formulation (calcipotriene 50 microg/g plus betamethasone 0.5 mg/g)
Number of subjects: 1505

Group type: COMPARATOR
Intervention: Betamethasone 0.5 mg/g (as dipropionate) in the same vehicle
Number of subjects: 1505

Group type: COMPARATOR
Intervention: Calcipotriene 50 microg/g in the same vehicle
Number of subjects: 1505

Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 1505
Study: 16235126

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted peritoneal catheter placement
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard transrectal or pararectal approach
Number of subjects: 100
Study: 12180317

Group type: EXPERIMENTAL
Intervention: F0 (braking force)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pmax (maximal anaerobic power)
Number of subjects: 36
Study: 10598609

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 274

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 274

Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 274
Study: 7489236

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 2037541

Group type: EXPERIMENTAL
Intervention: Fluconazole (50 mg in one single daily dose)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Amphotericin B (200 mg four times daily)
Number of subjects: 50
Study: 7044802

Group type: EXPERIMENTAL
Intervention: benoxaprofen
Number of subjects: 1403

Group type: COMPARATOR
Intervention: comparator drugs (diclofenac, indomethacin, flurbiprofen, piroxicam)
Number of subjects: 1403
Study: 30614222

Group type: EXPERIMENTAL
Intervention: Home-based environmental control intervention (INT)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 222
Study: 26443484

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine oral rinse
Number of subjects: 94

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 94
Study: 24528246

Group type: EXPERIMENTAL
Intervention: High-dose metformin (50% reduction)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discontinuation of glimepiride
Number of subjects: 0
Study: 22958507

Group type: EXPERIMENTAL
Intervention: WATER therapy program (24 sessions, 3 times/week over 8 weeks) of low-intensity exercises in a warm pool (32°C)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: WATER therapy program
Number of subjects: 66

Group type: COMPARATOR
Intervention: CONTROL group (usual care treatment for breast cancer)
Number of subjects: 66
Study: 19687337

Group type: EXPERIMENTAL
Intervention: 12 weeks of supervised aerobic exercise training (AET)
Number of subjects: 122
Study: 17595415

Group type: EXPERIMENTAL
Intervention: 15 mg Zn/d for 6 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 30 mg Zn/d for 6 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Total Zn intake (diet plus supplementation) of up to 40 mg Zn/d
Number of subjects: 100
Study: 15964291

Group type: EXPERIMENTAL
Intervention: Nestorone/ethinyl estradiol ring releasing 50/10 mug/day
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Nestorone/ethinyl estradiol ring releasing 50/20 mug/day
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Nestorone/ethinyl estradiol ring releasing 150/15 mug/day
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Nestorone/ethinyl estradiol rings (all doses)
Number of subjects: 160
Study: 11929402

Group type: EXPERIMENTAL
Intervention: Celecoxib (800 mg/day)
Number of subjects: 3993

Group type: COMPARATOR
Intervention: Diclofenac (150 mg/day)
Number of subjects: 3993
Study: 10064240

Group type: EXPERIMENTAL
Intervention: Itraconazole, 2.5 mg/kg every 12 hours
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study: 7501737

Group type: EXPERIMENTAL
Intervention: 35% CO2 inhalation
Number of subjects: 99
Study: 2083942

Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 191

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 191
Study: 763004

Group type: EXPERIMENTAL
Intervention: Active Patient Orientation (APO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incremental changes in systems of routine clinic care
Number of subjects: 0
Study: 30834862

Group type: EXPERIMENTAL
Intervention: Quo-Test HbA1c POCT
Number of subjects: 266

Group type: COMPARATOR
Intervention: Standard treatment (Control group)
Number of subjects: 266
Study: 28715852

Group type: EXPERIMENTAL
Intervention: Intermittent drospirenone/ethinyl estradiol dosed on a 21-7 schedule (n = 17)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Continuous drospirenone/estradiol (n = 16)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 55
Study: 26232126

Group type: EXPERIMENTAL
Intervention: Probiotic milk containing Lactobacillus rhamnosos GG, L. acidophilus La‐5, and Bifidobacterium animalis subsp. lactis Bb‐12
Number of subjects: 415

Group type: COMPARATOR
Intervention: Placebo milk
Number of subjects: 415
Study: 24023537

Group type: EXPERIMENTAL
Intervention: Infant mental health intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced service as usual
Number of subjects: 0
Study: 20643863

Group type: EXPERIMENTAL
Intervention: Trabectedin plus pegylated liposomal doxorubicin (PLD)
Number of subjects: 672

Group type: COMPARATOR
Intervention: Single-agent PLD
Number of subjects: 672
Study: 19629666

Group type: EXPERIMENTAL
Intervention: Catheter ablation for atrial fibrillation (AF) - pulmonary veins antrum isolation (PVAI)
Number of subjects: 29
Study: 17432401

Group type: COMPARATOR
Intervention: Control group (flowable and microhybrid resin composites)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 7 (flowable A + microhybrid resin A + post A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 8 (flowable B + microhybrid resin B + post B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 6 (flowable B + microhybrid resin B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 5 (microhybrid resin B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 4 (microhybrid resin A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 2 (flowable A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 3 (flowable B)
Number of subjects: 80
Study: 15112862

Group type: EXPERIMENTAL
Intervention: Test formulation (Penopril)
Number of subjects: 24